As a case in point, single use of EGFR inhibitors does not lead to significant tumor remission or prolonged stabilization rates in unselected patients with colorectal cancer, non-small cell lung cancer, breast cancer, or HNC among other entities [29, 36–39]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.